FDA’s Controversial Vaccine Chief Vinay Prasad to Exit Agency Again OR Vinay Prasad Leaving FDA Amid Rare Disease Drug Disputes & Management Concerns

WASHINGTON — Vinay Prasad, a physician and top official at the Food and Drug Administration whose tenure has been marked by controversy, is leaving the agency at the end of April. The departure of Prasad, who oversaw the Center for Biologics Evaluation and Research (CBER), comes amid increasing scrutiny of the FDA’s decision-making process, particularly regarding approvals of rare disease therapies.

FDA Commissioner Marty Makary confirmed Prasad’s exit to The Wall Street Journal. Prasad did not immediately respond to requests for comment, according to STAT News.

A Tumultuous Tenure at CBER

Prasad’s time at the FDA has been anything but smooth. Initially fired in July 2025 by Commissioner Makary after sparking outrage among rare disease advocates and political figures with his handling of a Duchenne muscular dystrophy treatment, he was surprisingly reinstated just weeks later. This reversal underscored the complex dynamics at play within the agency and the influence of external pressures. His return was followed by a series of personnel changes, including the removal of the head of vaccine safety and surveillance, with Prasad installing himself in the role. Eight agency officials described a function environment characterized by mistrust and paranoia, according to STAT News.

As director of CBER, Prasad was responsible for regulating vaccines, gene therapies and blood products. He also led a committee evaluating drugs granted “Commissioner’s National Priority Voucher,” a program designed to expedite regulatory decisions. This role gave him broad influence over drug approvals beyond his direct purview.

Shifting Standards for Rare Disease Approvals

One of the most significant points of contention during Prasad’s leadership has been the agency’s approach to rare disease drugs. Even as Makary publicly emphasized regulatory flexibility, CBER under Prasad increased scrutiny of these therapies, rejecting at least five cell and gene therapies that experts believed would have been approved under previous administrations. These decisions have raised concerns among rare disease patient advocates, who question whether the FDA’s actions align with its stated goals.

Drugmakers have accused the FDA of reversing previously agreed-upon clinical trial designs, leading to unexpected rejections. For example, a drug for a rare blood cancer was on track for approval before being rejected last month due to concerns about clinical data the company thought had already been addressed. This inconsistency has created uncertainty for companies developing therapies for small patient populations.

Broader Policy Shifts and White House Involvement

Prasad’s departure follows a recent public rebuke of an experimental Huntington’s treatment by a senior official from the Department of Health and Human Services, an unusual step that involved discussing a therapy still under regulatory review. This incident, coupled with the changes to rare disease drug approvals, reflects a broader shift in the FDA’s approach under the Makary administration.

The FDA, under Makary and with Prasad’s involvement, has been implementing changes aimed at accelerating drug approvals, including mandating the use of artificial intelligence and offering expedited assessments for drugs deemed to be of “national interest.” However, these efforts have been met with criticism from some quarters, who argue that they may compromise patient safety and scientific rigor. The agency’s approach to vaccines has also drawn scrutiny, with Prasad and Tracy Beth Høeg reportedly wresting control of vaccine surveillance from career staff. In February 2026, Prasad initially overruled staff recommendations to review a new flu vaccine from Moderna, a decision that was later reversed following pressure from the White House.

A Changing Landscape at the FDA

The FDA’s evolving policies are occurring within a broader context of a more vaccine-skeptical approach under Health and Human Services Secretary Robert F. Kennedy Jr., a known critic of vaccines. Prasad’s departure adds another layer of complexity to the agency’s leadership and raises questions about the future direction of drug regulation in the United States.

Prasad’s work style also contributed to the tension. He reportedly required staff to share their calendars with him while keeping his own private and discouraged them from informing their supervisors when he requested meetings. These practices led to complaints to human resources from several employees, according to reports.

Looking Ahead: What’s Next for CBER and the FDA

The FDA has not yet identified a replacement for Prasad. The search for a new CBER director will be closely watched by the pharmaceutical industry, patient advocacy groups, and public health officials. The agency faces ongoing challenges in balancing the need for faster drug approvals with the imperative of ensuring patient safety and scientific integrity. The agency will also need to navigate the political landscape and address concerns about transparency and accountability in its decision-making processes. The ongoing review of the Commissioner’s National Priority Voucher program, and the agency’s overall approach to rare disease therapies, will likely be key areas of focus in the coming months.